We improve the potency of antibody-drug conjugates (ADCs) containing the human epidermal growth factor receptor 2 (HER2)-specific antibody pertuzumab by substantially reducing their affinity for HER2 at acidic endosomal pH relative to near neutral pH. These engineered pertuzumab variants show increased lysosomal delivery and cytotoxicity towards tumor cells expressing intermediate HER2 levels. In HER2 int xenograft tumor models in mice, the variants show higher therapeutic efficacy than the parent ADC and a clinically approved HER2-specific ADC.
Antibody-drug conjugates (ADCs) combine the high specificity of antibodies with the potent cytotoxicity of drugs 1, 2 . However, therapeutic efficacy of current ADCs requires relatively high levels of expression of the tumor target 1, 2 . Although increased payload delivery could be achieved by delivering higher ADC doses, this approach can lead to unacceptable toxicities towards normal cells 3, 4 . In addition, ADC treatment can result in a reduction of surface biomarker levels, further narrowing the therapeutic window 5 . A possible pathway towards overcoming these limitations is to generate ADCs that deliver their payload more efficiently to target cells. The majority of current ADCs are designed to enter lysosomes following internalization into cells 1, 2 . Typically, ADCs have high affinity for their target at endosomal, acidic pH, and payload delivery is associated with entry of the target into degradative lysosomal compartments 1, 2 . Engineering the ADC to confer endosomal dissociation from its target is expected to enable payload entry into lysosomes and recycling of unbound target. A possible strategy towards achieving this is to generate engineered 'acid-switched' ADCs that bind target with substantially higher affinity at near neutral, extracellular pH relative to acidic endosomal pH, leading to endosomal dissociation of the ADC following internalization into cells.
Human epidermal growth factor receptor 2 (HER2) is a validated target for the treatment of HER2-overexpressing tumors, and several antibody-based therapies that include pertuzumab 6 and the ADC trastuzumab-DM1 (T-DM1) 7 are approved for clinical use. However, targeting HER2 with T-DM1 has met with disappointing results for HER2-positive tumors that do not overexpress this receptor 2, 8 , supporting the need to develop ADCs with improved drugdelivery properties. Here, we have generated acid-switched variants of the HER2-specific antibody pertuzumab 6 for use as ADCs. Analysis of the interactions of trastuzumab 9 and pertuzumab 6 with recombinant HER2-ECD (HER2 extracellular domain-Fc fusion) demonstrated that although the affinity of trastuzumab for HER2 is similar across the pH range 6.0-7.4, the affinity of pertuzumab is around tenfold higher at pH 7.4 than pH 6.0 ( Supplementary  Fig. 1 ). On the basis of earlier studies using parent antibodies with some intrinsic pH-dependence as starting templates to produce antibodies with increased pH-dependent binding to their soluble targets [10] [11] [12] , we chose pertuzumab for engineering to generate acidswitched variants.
First, residues of the complementarity-determining region (CDR) that either directly interact with, or are in proximity to, HER2 residues 6 were mutated to histidine ( Supplementary Fig. 2a ). Second, CDR residues were randomly mutated to generate phagedisplay libraries followed by panning against HER2-ECD to isolate acid-switched variants ( Supplementary Fig. 2b ).
Using histidine replacement, two mutated variants of pertuzumab (Y55H, CDRL2; S103H, CDRH3) were combined to generate the acid-switched variant 'YS' (Y55H-VL/S103H-VH) ( Supplementary Fig. 2c ). An acid-switched variant with S55H and G57E ('SG') mutations in CDRH2 was also selected using phage display ( Supplementary Figs. 2d and 3 ). The binding of YS and SG (as human IgG1/κ) to HER2 was analyzed at different pH values ( Supplementary Fig. 4 ). YS and SG have similar affinities for HER2 at pH 7.4, whereas the binding affinities of SG decrease more than those of YS as the pH is lowered ( Supplementary Fig. 4 ). Both YS and SG showed favorable stability, including in human serum ( Supplementary Fig. 5 ).
We conjugated wild-type pertuzumab, YS and SG through hinge cysteines to maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E (MC-VC-PAB-MMAE). We chose this over random conjugation of lysines to the maytansinoid DM1 to facilitate the generation of homogeneously conjugated ADCs. MMAE is also the most commonly used cytotoxic drug for ADCs currently in clinical use 3 . The cysteines that form disulfide bonds in the hinge or hinge/Cκ domain (Cys220, Cys229 of heavy chain; Cys214 of light chain) were mutated to serines to enable conjugation to Cys226 with a drug-antibody ratio (DAR) of two. This conjugation level was used to reduce the hydrophobicity reported for ADCs with higher DARs 13 . Hydrophobic interaction and size exclusion column analyses indicated that the DARs range from 1.7 to 1.9 with no indication of aggregation ( Supplementary Fig. 6a ).
The ADCs were also stable in human serum and retained similar binding properties for HER2 as their parent, unconjugated antibodies ( Supplementary Fig. 6b,c) .
We next investigated the accumulation of SG-MMAE and YS-MMAE in tumor cell lines expressing HER2 at different levels 14, 15 ( Supplementary Fig. 7 ). To quantitate the intracellular accumulation of the acid-switched pertuzumab-MMAE variants, cells were treated with Alexa 488-labeled ADCs and then surface signal was quenched using an Alexa 488-specific antibody 15, 16 (Fig. 1 ). Higher intracellular levels of YS-MMAE and SG-MMAE were observed in all HER2-expressing cells following incubation for 4 and 20 h compared with wild-type pertuzumab conjugated to MMAE (WT-MMAE), with greater levels of SG-MMAE relative to YS-MMAE (Fig. 1) . In addition, both SG-MMAE and YS-MMAE accumulated more efficiently than WT-MMAE in lysosomes within HER2 int MDA-MB-453 cells ( Supplementary Fig. 8 ). The acid-switched pertuzumab variants, or ALTAs (for ADCs with increased lysosomal-trafficking activity), were more effective than WT-MMAE in reducing the viability of the HER2 int cell lines, MDA-MB-453 and JIMT-1 and one HER2 hi cell line, SK-OV-3 (Fig. 2a) . The ALTAs showed similar cytotoxicity as WT-MMAE towards two other HER2 hi cell lines, SK-BR-3 and HCC1954 and the HER2-negative cell line, MDA-MB-468 14 . It is possible that internalization of a relatively low proportion of surface HER2 molecules is sufficient for cytotoxicity towards HER2-overexpressing cells, leading to lower dependence on endosomal HER2-ADC dissociation and ADC reloading. Quantitative analyses using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) also demonstrated increased MMAE levels in MDA-MB-453 and JIMT-1 cells following treatment with SG-MMAE or YS-MMAE compared with WT-MMAE (Fig. 2b) .
Analyses in BALB/c SCID mice demonstrated that WT-MMAE, SG-MMAE and YS-MMAE have similar pharmacokinetic behavior ( Supplementary Fig. 9 ). The therapeutic effects of the ALTAs were next compared with WT-MMAE and T-DM1 in mouse xenograft models expressing intermediate HER2 levels. We used T-DM1 instead of trastuzumab-MMAE as a comparator to benchmark the activity of the ALTAs with this clinically approved, HER2-specific ADC. A dose (2 mg kg −1 ) that is suboptimal for T-DM1 14 was used to evaluate whether the ALTAs had greater anti-tumor effects. Treatment with SG-MMAE or YS-MMAE was more effective than WT-MMAE, T-DM1 or wild-type pertuzumab (unconjugated) in inhibiting the growth of MDA-MB-453 xenografts, with three mice in the SG-MMAE group (n = 8) having undetectable tumors at the experimental endpoint ( Fig. 2c and Supplementary Fig. 10a ). We also treated mice bearing JIMT-1 tumors, which are relatively resistant to T-DM1 14 , with 2 mg kg −1 SG-MMAE, WT-MMAE, T-DM1 and, as controls, unconjugated wild-type pertuzumab or SG (Fig. 2d) . The therapeutic effect of SG-MMAE was significantly higher than that of WT-MMAE, T-DM1 and unconjugated control antibodies ( Fig. 2d and Supplementary Fig. 10b ). In all therapy experiments, ADCs were well tolerated with no weight loss or indication of liver toxicity ( Supplementary Fig. 10c,d) .
We also carried out modeling studies to investigate the molecular basis of the reduced affinity at pH 5.8 of the lead acidswitched antibody, SG, for HER2 relative to wild-type pertuzumab ( Supplementary Fig. 11 ). These analyses resulted in a model in which protonation of His55 in CDRH2, that replaces Ser55 in wildtype pertuzumab, at Nε of the imidazole ring predominates over that of Nδ1 at near neutral pH, whereas the protonated Nδ1 tautomer is favored at acidic pH (5.8). Protonation of Nδ1 leads to an electrostatic interaction with Glu57 in CDRH2 of SG in combination with interactions with Tyr252 of HER2. In contrast to the solvent exposure of Glu57 and Tyr252 in the SG-HER2 complex at pH 7.4, the change in protonation state of histidine at pH 5.8 results in reorientation of Glu57 and Tyr252, leading to an unfavorable desolvation penalty that is a primary contributor to the loss of affinity of SG at acidic pH.
Observations made during the use of ADCs in the clinic have indicated that dose-limiting toxicities for these therapeutics are usually 'off-target' rather than 'on-target/off-tumor' 3, 4 . Although the processes leading to off-target toxicities are currently not well understood, ADC entry into cells via non-specific pathways such as fluid-phase pinocytosis is a probable contributor. Furthermore, endocytosis into Fcγ-receptor-expressing cells may play a role 3, 4 . Consequently, the generation of ADCs such as ALTAs that achieve therapeutic effects at lower doses is expected to lead to reduced undesirable toxicities. In this context, the activity of the IgGrecycling receptor, FcRn, in normal epithelium 17, 18 , could also regulate the subcellular trafficking behavior of ALTAs to decrease both on-and off-target toxicities, in contrast to reports that this receptor can be at low to undetectable levels in breast, prostate or lung cancer cells 19, 20 . In summary, we have described ADCs comprising acid-switched pertuzumab variants which, on the basis of improved intracellular trafficking, result in increased payload delivery to target cells. These ALTAs have higher therapeutic efficacy against HER2 int tumor cells compared with ADCs containing the parent, wild-type antibody or T-DM1. It is possible that a similar strategy could be used to generate ADCs with improved efficacy against other tumor types and targets.
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Methods
Cell lines and reagents. The following cancer cell lines were obtained from the American Type Culture Collection: SK-BR-3, SK-OV-3, MDA-MB-453 and MDA-MB-468. SK-BR-3 and SK-OV-3 cells were cultured in McCoy's 5a medium, whereas MDA-MB-453 and MDA-MB-468 cells were cultured in RPMI1640 medium. The breast-cancer cell line JIMT-1 was obtained from AddexBio and cultured in DMEM medium. The HCC1954 cell line was a generous gift from A. Gazdar, J. Minna and K. Huffman (Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas) and was cultured in RPMI1640 medium. All media were supplemented with 1% penicillin/ streptomycin, 1% GlutaMAX (Thermo Fisher Scientific), 1% sodium pyruvate and 10% fetal calf serum. The cell lines were tested monthly for mycoplasma contamination and were authenticated annually at the University of Arizona Genetics Core through DNA fingerprint analysis.
Histidine scanning of pertuzumab. The sequences encoding the pertuzumab variable heavy (VH) and variable light (VL) chain domains 6 were synthesized by GenScript and used to generate an expression vector to produce pertuzumab Fab fragments (human CH1, Cκ; C-terminal polyhistidine tag on Cκ domain) using standard methods of molecular biology. Residues in the CDRs of the VH and VL domain genes of pertuzumab were selected for histidine scanning using the crystal structure of pertuzumab in complex with HER2 (Protein Data Bank accession code 1N8Z) 6 in PyMOL as a guide. The following residues, that are in proximity to or contact HER2, were targeted: Asp31, Tyr32, Asn54, Tyr60, Leu100, Gly101, Pro102, Ser103, Tyr105, Asp107 in the VH domain and Tyr55 in the VL domain. These residues were mutated to histidine using the PCR and standard methods and the corresponding Fab fragments were expressed as periplasmically secreted proteins using Escherichia coli as an expression host 21 . Fab fragments were purified using Ni 2+ -NTA-agarose 21 .
Generation of phage-display libraries.
To express pertuzumab as a single-chain Fv fragment (scFv) using the phagemid vector, pHEN1 22 , the expression vector for the pertuzumab Fab fragment was modified using standard methods of molecular biology to insert a linker peptide ((Gly 4 Ser) 3 Gly 2 Ser linker) between the pertuzumab VH and VL domain genes, followed by cloning into pHEN1 as a NotI-SfiI fragment. Libraries were generated with random mutations in CDR1, 2 and 3 of the VH domain (targeting Asp31, Tyr32 and Thr33; Asn75, Ser76, Gly77 and Gly78; Gly101, Ser103, Tyr105 and Tyr108) and CDR2 of the VL domain (targeting Ile48, Tyr49 and Ser50 or Ala51, Tyr53 and Tyr55). The following oligonucleotides were used in PCRs with standard methods to generate five libraries: library 1, CDRH1Back, 5 ′-GC TT CT GG AT TC AC AT-TC AC AN NB NN BN NB AT GG AT TGGGTGAGACAGGCT-3′ and CDRH1For, 5′-TGTGAATGTGAATCCAGAAGC-3′; library 2: CDRH2Back, 5′-TG GG TG GC-TG AT GT GA AT CC TN NB NN BN NB NN BT CT AT CTACAATCAGAGATTC-3′ and CDRH2For, 5′-AGGATTCACATCAGCCACCCA-3′; library 3: CDRH3Back, 5 ′-TA CT AC TG TG CT AG AA AT CT GN NB CC TN NB TT CN NB TT CG AT NN B TGGGGACAGGGAACACTG-3′ and CDRH3For, 5′-CAGATTTCTAGCACAGT AGTA-3′; library 4: CDRL2-1Back, 5′-CCTAAGCTGCTG ATCTACTCTNNBT CTNNBAGANNBACAGGAGTGCCTTCTAGA-3′ and CDRL2-1For, 5′-AGAGTAGATCAGCAGCTTAGG-3′; library 5: CDRL2-2Back, 5′-GGAAAG GCTCCTAAGCTGCTGNNBNNBNNBGCTTCTTACAGATACACAGGA-3′ and CDRL2-2For5, 5′-CAGCAGCTTAGGAGCCTTTCC-3′ (N = A, C, T or G; B = C, T or G). The resulting gene libraries were transfected into E. coli TG1 (Lucigen) to generate libraries of 2.6 × 10 6 -1.7 × 10 8 clones. Each library was pooled and grown overnight at 30 °C in 4XTY broth supplemented with M13KO7 helper phage (New England Biolabs), 100 µg ml −1 ampicillin and 50 µg ml −1 kanamycin. Phage were precipitated with a solution of PEG-8000 and NaCl at a concentration of 4% PEG-8000/0.5 M NaCl followed by centrifugation at 10,000 RCF. The precipitated phage were washed with 4% (w/v) PEG-8000/0.5 M NaCl before suspension in 1% (w/v) bovine serum albumin (BSA)/PBS. To select phage that display pertuzumabderived scFvs that bind to HER2 with increased pH-dependence, recombinant phage were first pre-panned in Nunc 96-well flat-bottom immuno plates (Thermo Fisher Scientific) coated with 4% (w/v) milk powder/PBS (pH 7.4), and subsequently transferred to 96-well Nunc plates that had been coated with 2 µg ml −1 recombinant HER2-ECD (R&D Research) and blocked with 4% (w/v) milk powder/PBS (pH 7.4). After a 2 h incubation, the plates were washed five times with PBS plus 0.1% Tween 20 (PBST) pH 7.4 followed by five washes with PBS pH 7.4. Bound phage were then eluted by the addition of 20 mM 2-(N-morpholino) ethanesulfonic acid pH 5.8 for 10 min. The eluted phage were amplified by reinfection of E. coli TG1, followed by two additional rounds of selection using ten washes with PBST pH 7.4 and ten washes with PBS pH 7.4. Eluted phage (pH 5.8) from the third round of panning were used to re-infect E. coli TG1, single clones expanded in 96-deep-well plates and treated with helper phage using previously described methods 22 . Culture supernatants containing phage were used in enzyme-linked immunosorbent assays (ELISAs) with plates coated with recombinant HER2-ECD, followed by washing with PBST pH 7.3 or pH 5.8. Bound phage were detected using anti-M13 antibody conjugated to horse radish peroxidase (HRP) (GE Healthcare) at a 1:5,000 dilution in 4% milk powder in PBS, pH 7.3 or 5.8, followed by detection with 3′3′5,5′ tetramethylbenzidine substrate. For ELISAs using purified phage, phage suspensions were added to each well and binding at pH 5.8 and 7.4 was detected using the same protocol.
Recombinant antibodies. VH and VL domain genes encoding wild-type or acidswitched pertuzumab variants (obtained by histidine scanning or phage display) were used to generate constructs for the expression of full-length human IgG1, Cκ antibodies using standard methods of molecular biology and the vector, pcDNA3.4-TOPO (Life Technologies). The hinge disulfide bonds that link the Cκ domain to the hinge region and one hinge disulfide that links the two heavy chains to each another were removed by mutating the light-chain cysteine (Cys214; EU numbering) and two heavy chain cysteines (Cys220, Cys229; EU numbering) to serine. Sequences of expression plasmids are available from the authors upon request.
For use as a control antibody, the VH and VL domains of the hen-egg lysozyme antibody, HuLys10 23 , were reformatted as heavy-and light-chain constructs to generate a full-length human IgG1/κ antibody with one hinge disulfide (as above) using pcDNA3.4-TOPO.
Recombinant antibodies were produced in Expi293F cells (Life Technologies) following transient transfection with the Expi293 expression system kit (Life Technologies) as previously described 24 . Antibodies were purified from culture supernatants using protein G-Sepharose (GE Healthcare) and dialyzed against PBS. Purified antibodies were loaded onto a Hiload 16/600 Superdex 200 gel filtration column (GE Healthcare) to remove aggregates, followed by analyses of the 'monomeric' antibodies using a Yarra 3000 column (Phenomenex, Torrance, CA, USA).
Clinical grade trastuzumab and pertuzumab were acquired from the University of Texas Southwestern Medical Center Pharmacy. For full-length antibodies, equilibrium dissociation constants were determined using previously described methods 25 and custom written software (www.wardoberlab. com/software/sprtool) to yield apparent dissociation constants (due to bivalent binding of the antibodies to immobilized HER2). The K d of the YS mutant at pH 5.8 was too high to accurately determine (that is, levels of binding close to saturation could not be reached), and was therefore estimated using the following equation:
where K d is the calculated equilibrium dissociation constant (nM), C K is the concentration of analyte flowed over the chip (nM), R max is the maximum analyte binding capacity (RU), and R eq (C k ) is the equilibrium signal for concentration C K (RU).
Conjugation and labeling of antibodies. Antibodies (10 µM) in PBS were reduced by addition of 80 µM of Tris(2-carboxyethyl)phosphine (TCEP) and 1 mM EDTA for 2 h at 37 °C. Reduced antibodies were cooled on ice and 40 µM MMAE (Concortis) was added. After 4 h incubation on ice, unconjugated MMAE was removed by extensive dialysis against PBS. Conjugated antibodies were analyzed using size-exclusion chromatography (Yarra 3000) and hydrophobic interaction chromatography (TSKgel Butyl-NPR; Tosoh) to determine DARs. For hydrophobic interaction chromatography, solvent A was 10 mM potassium phosphate with 1. Serum stability analyses of antibodies and ADCs. Human serum (SigmaAldrich) was depleted of endogenous IgG by passage through a protein G-sepharose column. Antibodies and ADCs were incubated at a concentration of 40 µg ml −1 in IgG-depleted serum for 0, 3 or 5 d at 37 °C followed by immunoprecipitation using agarose beads coupled to goat anti-human Fc-specific antibody (Sigma-Aldrich). Immunoprecipitated antibodies and ADCs were run on SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (0.45 µm pore size; Genesee Scientific). Immunoblotting was carried out using standard methods with goat anti-human IgG (H + L) antibodies conjugated with HRP (Jackson Immunoresearch). HRP was detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) followed by scanning with a C-DiGit blot scanner (LI-COR Biosciences).
ADC accumulation assay.
Cancer cells were plated in 48-well plates and incubated overnight in a 37 °C incubator with 5% CO 2 , followed by treatment with 10 nM Alexa 488-labeled ADC in medium (pH 7.0) for 0.5, 4 and 20 h. Treated cells were cooled on ice and surface fluorescence of Alexa 488-labeled ADC quenched with 5 µg ml −1 rabbit anti-Alexa 488 antibody (Thermo Fisher Scientific) for 30 min at 4 °C. The quenching efficiency was determined using separate cell samples that had been incubated with Alexa 488-labeled ADC on ice (to prevent internalization) followed by treatment with anti-Alexa 488 antibody or vehicle control. Samples were washed, harvested by trypsinization, resuspended in PBS, analyzed using a BD Accuri C6 flow cytometer (BD Biosciences) and data processed with FlowJo (FlowJo).
Fluorescence microscopy. MDA-MB-453 cells were plated in coverglass-bottomed Mattek dishes and allowed to adhere overnight in a 37 °C, 5% CO 2 incubator. Cells were pre-treated with Alexa 647-labeled dextran (5 µM; pulsed for 2 h and chased for 3 h) followed by treatment with 10 nM Alexa 488-labeled WT-MMAE, SG-MMAE or YS-MMAE for 4 or 20 h. Samples were treated with 5 µg ml −1 rabbit antiAlexa 488 antibody for 30 min on ice to quench surface Alexa 488 fluorescence, and subsequently fixed at room temperature with 3.4% (w/v) paraformaldehyde plus 0.025% (v/v) glutaraldehyde. Fixed cell samples were imaged with an Axio Observer Z1 inverted epifluorescent microscope (Zeiss) equipped with a ×63, 1.4 NA PlanApochromat objective (Zeiss), and a Zeiss ×1.6 internal optovar. A broadband LED lamp (X-cite 110LED, Excelitas Technologies) was employed as the excitation source, and a digital CCD camera (Hamamatsu Orca-ER; Hamamatsu Photonics) as the detector. Standard fluorescent filter sets for Alexa 488 (FITC-3540C) and Alexa 647 (Cy5-4040C) were purchased from Semrock. Images were acquired at room temperature using custom software written in Java and the C programming language. Acquired images were analyzed using the custom written software MIATool (www.wardoberlab.com/software/miatool) 27 . Acquired images for Alexa 488 were linearly adjusted with the same intensity adjustment settings. Independent linear adjustments were made for the Alexa 647 signal for each time point.
Cell viability assays. Cells were plated in 96-well plates at a density of 5,000 cells per well and treated with different concentrations of ADCs. Cells were treated for 4 d in a 37 °C, 5% CO 2 incubator, followed by the use of CellTiter 96 AQueous One Solution Proliferation Assay kit (Promega) to determine cell viability using the manufacturer's protocol.
Quantitation of MMAE using LC-MS/MS.
Cancer cells were plated in 6-well plates and incubated overnight in a 37 °C, 5% CO 2 incubator. Cells were treated with 10 nM ADC for 20 h, followed by washing with PBS and harvesting by trypsinization. Trypsinized cells were counted and resuspended in 100% methanol containing 1.67 ng ml −1 deuterium-labeled MMAE (D8-MMAE; MedchemExpress) at a density of 8.3 × 10 5 cells ml −1
. Samples were lysed for 16 h at −20 °C and then centrifuged at 21,100 RCF for 15 mins at 4 °C. The supernatants were transferred to 12 × 75 mm borosilicate glass tubes (Kimble Chase) and dried under a stream of nitrogen gas. The residue was resuspended in 20% methanol with 0.1% (v/v) formic acid (10% of original volume). To generate a standard curve, different concentrations of MMAE ranging from 0.017 to 3.33 ng ml −1 were mixed with 1.67 ng ml −1 D8-MMAE in lysates of untreated tumor cells and treated as above. Targeted LC-MS/MS analysis was performed using a Quantiva triple quadrupole mass spectrometer (Thermo Fisher Scientific) coupled to binary pump highperformance liquid chromatography (Ultimate 3000; Thermo Fisher Scientific). Chromatographic separation was achieved on a Hypersil Gold 5 µm, 50 mm × 3 mm column (Thermo Fisher Scientific) maintained at 30 °C using a solvent gradient method. . The sheath, auxiliary and sweeping gasses were set at 50, 15 and 1 arbitrary units, respectively. The spray voltage was set to 3.5 kV and the vaporizer and capillary temperatures were maintained at 375 °C and 350 °C, respectively. Transitions of 718.8-134.1 m/z and 727.6-134.1 m/z were used for the quantitation of MMAE and D8-MMAE, respectively. Sample acquisition and data analysis were performed using TraceFinder (Thermo Fisher Scientific).
Pharmacokinetic analyses.
Pharmacokinetic experiments were carried out in 7-10-week-old female BALB/c SCID mice using protocols approved by the Texas A&M University IACUC. Lugol solution (Sigma-Aldrich) was added to drinking water 48-72 h before starting the experiment, and maintained throughout the experiment. Mice were injected intravenously with 15 µg 125 I-labeled ADC in 200 µl PBS with 0.1% (w/v) BSA. Whole body counts were measured using an Atom Lab 100 dose calibrator (Biodex) as described previously 26 and β-phase half-lives determined by fitting exponentially decaying models to the data using gradient-based numerical optimization methods written in MATLAB. Mice were retroorbitally bled with 10 µl capillary tubes (Drummond Scientific) and radioactive counts measured by gamma counting (Perkin Elmer). Radioactivity counts were normalized to the values obtained immediately following injection.
Therapy experiments. Therapy experiments were carried out using protocols approved by the Texas A&M University IACUC. BALB/c SCID mice were purchased from Jackson Laboratories, bred and maintained in specific pathogenfree housing. 6-8-week-old female mice were implanted with 3 × Modeling analyses. The X-ray crystallographic structure of the HER2-pertuzumab complex 6 (Protein Data Bank accession code: 1S78) was minimized using the molecular-modeling software CHARMM v.36 in a CHARMM22 force field, and all missing residues and atoms were added 28 . PROPKA v.3.1 29 was used for empirical pK a prediction and protonation state determination for the minimized structure at pH 7.4 and 5.8, respectively. The resulting structure at either pH value was minimized for 5,000 steps with explicit solvent molecules and then subjected to a 10 ns molecular dynamics simulation using the computer program NAMD2 v.2.10 28 . Molecular dynamics protocols followed similar details as described previously 28 . Snapshots were retained at 0 ns (the beginning) and every 1 ns from 6 to 10 ns to represent a conformational ensemble of the HER2-pertuzumab complex at either pH.
Structures of HER2 in complex with the SG mutant were modeled using interconnected cost function networks (iCFN) 30 , an exact algorithm for multistate protein design with substate ensembles, which was customized here for pH dependence. First, the positive and negative substates were defined as conformational ensembles of the complex at pH 7.4 and 5.8, respectively. Substate energies were folding stabilities of the complex that include Coulomb electrostatics, van der Waals, calculated internal energies and a nonpolar contribution to the hydration free energy on the basis of solvent-accessible surface area (SASA) 30 . A positive-substate stability cutoff was set at 10 kcal mol −1 and positive-versusnegative substate specificity was essentially not mandated with a cutoff of 1,000 kcal mol
. Second, pertuzumab VH residues 55 and 57 were allowed to change to any amino acid, including histidines in δ-, ε-and doubly protonated states. Residues within 5 Å of the mutated amino acids were allowed to be flexible. In addition, His245 of HER2 was allowed to be in any of the three possible protonation states and Asp50 of pertuzumab VH was allowed to be deprotonated or singly protonated at either oxygen atom on the side chain. Top conformations of each sequence-protonation combination in each substate (backbone conformation here) generated from iCFN for either pH were geometrically grouped into representatives and then screened by PROPKA for protonation states. Later, complex-folding stabilities (G) and binding affinities (∆G) of the top sequenceconformation ensembles retained for either pH were reevaluated and reordered with a higher-resolution energy model where continuum electrostatics replaced Coulombic electrostatics 30 . Lastly, the representative conformation/protonation at either pH was chosen on the basis of the best binding affinity (lowest ∆G) amongst those whose folding energies were within 1 kcal mol −1 of the most stable complex. Each calculated binding energy relative to the wild type, ∆∆G, was further decomposed into contributions of van der Waals, continuum electrostatics, SASAdependent nonpolar solvation interactions and internal energy. Van der Waals and electrostatics were found to be the most important contributors to pH-dependent binding. The calculated van der Waals contribution was largely due to the modeled clashes between the bulkier pertuzumab His55 and a HER2 loop at pH 5.8 whereas the clashes could be largely ameliorated by the flexible HER2 loop. Therefore, longrange electrostatic binding affinity, being less sensitive to conformational details, was further analyzed as an origin of the pH-dependent binding. Specifically, continuum electrostatics for binding were first decomposed into the contributions of the lost desolvation penalties and the gained solvent-screened intermolecular interactions. Desolvations were then decomposed into contributions of all residues and screened intermolecular electrostatic interactions were decomposed into those of all residue pairs. To sum up screened intermolecular electrostatic interactions and avoid double counting for each residue, half of the pairwise interactions for each residue with all other residues were considered. Those residues with insignificant contributions (desolvation plus the half of the summed pairwise interactions) to electrostatic binding specificity ∆∆∆G (∆∆∆G = ∆∆G pH 7.4 − ∆∆G pH 5.8 ) were not considered further. Since desolvation penalties dominated over screened electrostatic interactions in contributions to electrostatic binding specificity ∆∆∆G, the top ten remaining residues with the highest desolvation contributions were reported for ∆∆G pH 7.4 , ∆∆G pH 5.8 and ∆∆∆G, respectively. Statistical analyses. Statistical significance was analyzed using two-tailed t-test, two-tailed Mann-Whitney U-test or one-way analysis of variance with Tukey's multiple-comparison test as indicated in the figure legends.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code Data collection Biacore T200 Control Software was used to acquire the surface plasmon resonance data. The flow cytometry data was acquired using the BD Accuri C6 software (version 1.0.264.2). Immunoblot data was acquired with the LiCor Image Studio Digits Ver 3.1. Microscopy data was obtained with custom written software. Both size exclusion and hydrophobic interaction column data were acquired with the LabSolutions Lite software provided by Shimadzu Corporation. ELISA, MTS assay, and ALT assay readings were taken by the KinetiCalc (Version #3.4 Rev #21) program. Mass spectrometry data was acquired with TraceFinder.
Data analysis
Custom written software in MATLAB (available at www.wardoberlab.com/software/sprtool) was used to process the acquired surface plasmon resonance data. Half-life estimations for pharmacokinetic analyses in mice were determined by fitting exponentially decaying models in MATLAB (software is available upon request). All flow cytometry data was analyzed using FlowJo. Flow cytometry histograms were produced and analyzed in FlowJo and mean fluorescent intensity values were exported to Excel to be processed. Liquid chromatography data was acquired with the LabSolutions Lite software. Pymol was used to analyze the Pertuzumab:HER2 crystal structure (Protein Data Bank: 1S78). Graphpad was used for both plotting and statistical analyses of tumor size, ALT activity, body weight, ELISA, and dose response curves. Mass spectrometry data was analyzed with TraceFinder. Acquired imaging data was analyzed with custom written software in MATLAB (available at www.wardoberlab.com/software/miatool). A combination of PROPKA v.3.1, CHARMM v36, and NAMD2 v.2.10 were used for modeling analysis.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that supports the findings in this study are available upon request from the corresponding author.
Field-specific reporting Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
We determined the number of mice used per group using the resource equation Data exclusions There were no data exclusions from the data provided.
Replication
The replication number is indicated in the legend of corresponding figures where applicable. Replication of experiments generated similar results as indicated in the Figure legends. Crystal structure analysis ( Supplementary Fig. 2 ) was not replicated. Modeling simulation ( Supplementary Fig. 11 ) was not replicated as the algorithm iCFN is exact.
Randomization No specific randomization was done for in vitro experiments or assays shown in Figs. 1, 2b , supplementary Figs. 8 and 10c. Samples in Fig. 2a were randomly positioned in the 96-well plates to ensure that there was no positional bias on the plate. For pharmacokinetic experiments using mice, mice were randomly assigned into treatment groups, and mice in different treatment groups were caged together to avoid cage effects. For therapy experiments using mice, tumor-bearing mice were assigned into treatment groups so that the mean tumor size for each group was similar at the start of treatment, and mice in different treatment groups were caged together to avoid cage effects.
Blinding
No blinding was carried out during allocation of mice to treatment groups. For tumor sizes and weight measurements following the start of therapy, there were two scorers (one blinded, one non-blinded), and the blinded one took measurements at a lower frequency with similar results.
Behavioural & social sciences study design All studies must disclose on these points even when the disclosure is negative. Reporting for specific materials, systems and methods
Study description

Specimen deposition
Indicate where the specimens have been deposited to permit free access by other researchers. Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Dating methods
Recruitment
Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.
ChIP-seq Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links
May remain private before publication. 
Files in database submission
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
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Methodology Sample preparation
Cancer cells were treated in 48 well plates as described in the Methods. Cells were then harvested by trypsinization and washed with phosphate buffered saline.
Instrument
BD Accuri C6 flow cytometer.
Software
Cell population abundance BD Accuri C6 software (version 1.0.264.2) was used to acquire the data on the flow cytometer. FlowJo was used to determine mean fluorescence intensities. Exported mean fluorescence intensity values were analyzed in Graphpad. Histograms were produced in FlowJo.
We used homogenous cancer cell lines and did not sort our cells.
Gating strategy
We gated upon the population of single cells based on FSC and SSC values.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance imaging
Experimental design
